Deliverthera
1 known investors
Ponce Aurora (deliverthera.com) develops small molecule kinase inhibitors discovered through DNA-encoded library (DEL) screening, including a multi-kinase inhibitor targeting ABL1-T315I and other tyrosine kinases for patients with Ph+ acute lymphocytic leukemia. The company also develops selective JAK/TYK2 inhibitors as senomorphic therapies to regulate the senescence-associated secretory phenotype (SASP) in aging and age-related diseases.
Investors · 1
Frequently asked questions
- What does Deliverthera do?
- Ponce Aurora (deliverthera.com) develops small molecule kinase inhibitors discovered through DNA-encoded library (DEL) screening, including a multi-kinase inhibitor targeting ABL1-T315I and other tyrosine kinases for patients with Ph+ acute lymphocytic leukemia. The company also develops selective JAK/TYK2 inhibitors as senomorphic therapies to regulate the senescence-associated secretory phenotype (SASP) in aging and age-related diseases.
- Who are Deliverthera's investors?
- Deliverthera's investors include Rapha Capital Management, LLC.